Humanigen Inc (HGENQ)

[cowtown jay]

The earliest patent application for developing humanized antibodies was filed in 2015. The patent was granted to Humanigen in 2021.

More recently, another patent was filed in 2018, and granted to Humanigen in 2020. The following month, another patent was granted for CAR-T use. There were other patent grants, as well.

So it appears lenz has met your requirement of, "...any new drug needs at least 5-10 years of data," based on the 2015 and 2018 patent filings, which were granted.

Lenz wasn't in a Phase III trial, it had completed it, and successfully met the primary endpoint. I normally provide links, but you have shown me that such substantiation means nothing to you.

Lenz was sold to whom "for nothing?" Our CEO. And we know that preparations have been made for Taran to issue stock. Why? For a stock-for-stock merger?

I agree that lenz has multiple use applications. I consider it like WD-40, but I like your analogy to baking soda, as well.

And I know you realize that neither Pfizer, Moderna, nor mRNA technology have as much data history that lenz has, but they are authorized.

And perhaps you further realize that the mRNA vaccines are CAUSING injuries and excess deaths?

But Humanigen's success is on the horizon.